Innovations in molecular diagnostics
leading to automation of instruments are resulting in expanded
applications of molecular assay beyond just identification purposes. The
automated molecular assays having reduced handling errors and enhanced
limits of detection and quantitation are leading to the usage of
molecular assays in therapeutic monitoring and drug prescription
selection with an objective of avoiding toxicity and other side effects.
The shift in paradigm of clinical laboratory testing and medicine have
led to improved pharmacogenomics and patient stratification. Innovations
in the novel detection of pathogens and microRNAs are contributing to
the continued expansion of the market by changing the landscape of
personalized care. Advancements in automated molecular assays are
resulting in the elimination of discriminatory testing necessities for
patients.
Based on region, the Automated Molecular
Assay market can be segmented into North America, Europe, Asia Pacific,
Latin America, and Middle East & Africa. North America is
anticipated to dominate the global market during the forecast period due
to strong distribution networks of major market players, advances in
molecular diagnostics leading to early detection of metabolites,
proteins, DNA or RNA, and availability of skilled workforce to handle
the instrumentation of automated assay. Asia Pacific is likely to
witness an exponential growth during the forecast period, due to
improvements in healthcare infrastructure, increasing number of regional
manufacturers offering affordable yet technologically advanced
products, and rising investments in research and development for
innovations in the screening methodologies.
Development of proper reimbursement policies serve as a major opportunity for the global market. Multiple pathogen detection assays through advancements in the in-vitro detection techniques including genomics and proteomics are a growing trend in the global automated molecular assay market. Innovations in automated molecular assays include the ability to detect new variants of viruses, modifications in the genome of pathogens, and others. New product launches in the global market are primarily focused on detection of novel oncologic biomarkers, so as to allow the early detection of cancer.
Key players operating in the global
automated molecular assay market include F. Hoffmann-La Roche Ltd,
Luminex Corporation, Molecular Devices, LLC, Becton, Dickinson and
Company, Siemens Healthcare GmbH, Tecan Trading AG, Agilent Technologies
Inc., Thermo Fisher Scientific Inc., Invivoscribe, and Myriad Genetics,
Inc. among others.
The report offers a comprehensive
evaluation of the market. It does so via in-depth qualitative insights,
historical data, and verifiable projections about market size. The
projections featured in the report have been derived using proven
research methodologies and assumptions. By doing so, the research report
serves as a repository of analysis and information for every facet of
the market, including but not limited to: Regional markets, technology,
types, and applications.
No comments:
Post a Comment